Literature DB >> 28540696

Negative conversion of high serum p53 antibody titers in a patient with gastric cancer at 31 months after surgery.

Kenji Murayama1,2, Tatsuki Nanami1, Takashi Suzuki1, Yoko Oshima1, Satoshi Yajima1, Tetsuo Nemoto3, Hideaki Shimada4,5.   

Abstract

We performed distal gastrectomy with D2 lymph node dissection, pathological stage was Stage IB (T2N0M0), in a 68-year-old male with gastric adenocarcinoma. We then monitored serum p53 antibody titers for 5 years and found it consistently decreased, without disease recurrence. Although the s-p53-Ab titer remained positive even after 2 years, it decreased to 16.5, 4.45, 2.66, 1.55, and 1.18 U/ml at 3 months, 7 months, 1 year, 2 years and 3 years after surgery, respectively. The s-p53-Ab titer finally converted from positive to negative at 31 months postoperatively without any sign of recurrence by computed tomography examination at 5 years after surgery. This case report shows that the changing pattern of s-p53-Ab titer after surgery may be useful to identify patients without recurrence. Further studies are required to gain a more precise understanding of the clinical impact of s-p53-Ab titer monitoring in gastric adenocarcinoma.

Entities:  

Keywords:  Gastric cancer; Long-term monitoring; Postoperative; Recurrence; Serum p53 antibody

Mesh:

Substances:

Year:  2017        PMID: 28540696     DOI: 10.1007/s12328-017-0749-9

Source DB:  PubMed          Journal:  Clin J Gastroenterol        ISSN: 1865-7265


  14 in total

1.  Prognostic significance of serum p53 antibody in patients with esophageal squamous cell carcinoma.

Authors:  Hideaki Shimada; Yoshihiro Nabeya; Shin-Ichi Okazumi; Hisahiro Matsubara; Yutaka Funami; Tooru Shiratori; Hideki Hayashi; Akihiko Takeda; Takenori Ochiai
Journal:  Surgery       Date:  2002-07       Impact factor: 3.982

2.  Titration of serum p53 antibodies in patients with gastric cancer: a single-institute study of 40 patients.

Authors:  Keiji Shimizu; Yuji Ueda; Hisakazu Yamagishi
Journal:  Gastric Cancer       Date:  2005       Impact factor: 7.370

3.  Japanese classification of gastric carcinoma: 3rd English edition.

Authors: 
Journal:  Gastric Cancer       Date:  2011-06       Impact factor: 7.370

4.  The utility of tumor marker combination, including serum P53 antibody, in colorectal cancer treatment.

Authors:  Ryuma Tokunaga; Yasuo Sakamoto; Shigeki Nakagawa; Naoya Yoshida; Hideo Baba
Journal:  Surg Today       Date:  2017-01-06       Impact factor: 2.549

5.  Detection of preoperative serum anti-p53 antibodies in gastric cancer.

Authors:  K Nakajima; T Suzuki; H Shimada; H Hayashi; A Takeda; T Ochiai
Journal:  Tumour Biol       Date:  1999 May-Jun

Review 6.  Systematic review: serum autoantibodies in the early detection of gastric cancer.

Authors:  Simone Werner; Hongda Chen; Sha Tao; Hermann Brenner
Journal:  Int J Cancer       Date:  2014-03-06       Impact factor: 7.396

7.  Clinical significance of serum P53 antibody in patients with gastric cancer.

Authors:  G Shiota; M Ishida; N Noguchi; Y Takano; K Oyama; M Okubo; S Katayama; K Harada; K Hori; K Ashida; Y Kishimoto; A Hosoda; T Suou; H Ito; H Kawasaki
Journal:  Res Commun Mol Pathol Pharmacol       Date:  1998-01

8.  Perioperative changes of serum p53 antibody titer is a predictor for survival in patients with esophageal squamous cell carcinoma.

Authors:  Hideaki Shimada; Tooru Shiratori; Akihiko Takeda; Kazuyuki Matsushita; Shinichi Okazumi; Yasunori Akutsu; Hisahiro Matsubara; Fumio Nomura; Takenori Ochiai
Journal:  World J Surg       Date:  2009-02       Impact factor: 3.352

9.  Metabolic properties of IgG subclasses in man.

Authors:  A Morell; W D Terry; T A Waldmann
Journal:  J Clin Invest       Date:  1970-04       Impact factor: 14.808

10.  Long-term monitoring of serum p53 antibody after neoadjuvant chemotherapy and surgery for esophageal adenocarcinoma: report of a case.

Authors:  Hideaki Shimada; Matsuo Nagata; Akihiro Cho; Nobuhiro Takiguchi; Osamu Kainuma; Hiroaki Soda; Atsushi Ikeda; Yoshihiro Nabeya; Satoshi Yajima; Hiroshi Yamamoto; Takahiro Sugiyama; Makiko Itami
Journal:  Surg Today       Date:  2013-11-17       Impact factor: 2.549

View more
  4 in total

1.  Unusually high levels of serum p53 antibody in recurrent gastric cancer.

Authors:  Masaki Kunizaki; Keiko Hamasaki; Kouki Wakata; Shigekazu Hidaka; Takeshi Nagayasu; Yukie Kinoshita
Journal:  Clin J Gastroenterol       Date:  2017-09-26

2.  Five-year postsurgical monitoring of serum p53 antibody for locally advanced esophageal squamous cell carcinoma.

Authors:  Ryosuke Kochi; Satoshi Yajima; Tatsuki Nanami; Takashi Suzuki; Yoko Oshima; Natsuki Tokura; Jun Takatsuka; Kimihiko Funahashi; Naobumi Tochigi; Hideaki Shimada
Journal:  Clin J Gastroenterol       Date:  2018-03-01

3.  Using recursive partitioning approach to select tumor-associated antigens in immunodiagnosis of gastric adenocarcinoma.

Authors:  Jiejie Qin; Shuaibing Wang; Jianxiang Shi; Yan Ma; Keyan Wang; Hua Ye; Xiaojun Zhang; Peng Wang; Xiao Wang; Chunhua Song; Liping Dai; Kaijuan Wang; Binghua Jiang; Jianying Zhang
Journal:  Cancer Sci       Date:  2019-05-07       Impact factor: 6.716

4.  Longitudinal serum autoantibody repertoire profiling identifies surgery-associated biomarkers in lung adenocarcinoma.

Authors:  Yang Li; Cheng-Qiang Li; Shu-Juan Guo; Wei Guo; He-Wei Jiang; He-Cheng Li; Sheng-Ce Tao
Journal:  EBioMedicine       Date:  2020-02-26       Impact factor: 8.143

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.